Related Experiment Video
Updated: May 12, 2026
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Expression of CD133 in acute leukemia
Fetnat M Tolba1, Mona E Foda, Howyda M Kamal
1Clinical and chemical pathology, Faculty of Medicine, Benha University, Benha, Egypt.
Medical Oncology (Northwood, London, England)
|March 28, 2013
Summary
CD133 expression is linked to poorer outcomes in acute leukemias, particularly acute lymphoblastic leukemia (ALL). This marker indicates higher resistance to chemotherapy and relapse, suggesting it
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Conflicting data exists on the correlation between CD133 expression and disease outcomes in acute leukemias.
- CD133 is a cell surface glycoprotein investigated as a potential biomarker in various cancers.
Purpose of the Study:
- To investigate CD133 expression in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
- To evaluate the correlation of CD133 expression with clinical data, laboratory findings, and disease outcomes in acute leukemia patients.
Main Methods:
- Studied 60 newly diagnosed acute leukemia patients (30 ALL, 30 AML).
- Assessed CD133 expression on blast cells using flow cytometry.
- Correlated CD133 expression with clinical and laboratory data and patient outcomes.
Main Results:
- In ALL, negative CD133 expression correlated with higher complete remission rates.
- In AML, CD133 expression showed significant positive correlations with HLA-DR, CD3, CD7, TDT, CD13, and CD34.
- CD133 expression was negatively correlated with overall survival in AML patients.
- CD133 expression was not significantly associated with treatment outcome in AML.
Conclusions:
- CD133 expression is an independent prognostic factor in acute leukemia, especially ALL.
- CD133 expression identifies acute leukemia patients with potential resistance to chemotherapy and higher relapse rates.
- CD133 expression is strongly associated with a poor prognosis in acute leukemic patients.
